Affiliations: Integrative Oncology Department, BC Cancer Research Centre, Vancouver, BC, Canada | Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA
Note: [] Corresponding author: Gerald Li, Integrative Oncology Department, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, BC, Canada, V5Z 1L3. Tel.: +1 604 675 8000 Ext. 7089; Fax: +1 604 675 8099; E-mail: [email protected]
Note: [] Posthumous author.
Abstract: Background: Despite the benefits of early lung cancer detection, no effective strategy for early screening and treatment exists, partly due to a lack of effective surrogate biomarkers. Our novel sputum biomarker, the Combined Score (CS), uses automated image cytometric analysis of ploidy and nuclear morphology to detect subtle intraepithelial changes that often precede lung tumours. Methods: 2249 sputum samples from 1795 high-risk patients enrolled in ongoing chemoprevention trials were subjected to automated quantitative image cytometry after Feulgen-thionin staining. Samples from normal histopathology patients were compared against samples from carcinoma in situ (CIS) and cancer patients to train the CS. Results: CS correlates with several lung cancer risk factors, including histopathological grade, age, smoking status, and p53 and Ki67 immunostaining. At 50% specificity, CS detected 78% of all highest-risk subjects—those with CIS or worse plus those with moderate or severe dysplasia and abnormal nuclear morphology. Conclusion: CS is a powerful yet minimally invasive tool for rapid and inexpensive risk assessment for the presence of precancerous lung lesions, enabling enrichment of chemoprevention trials with highest-risk dysplasias. CS correlates with other biomarkers, so CS may find use as a surrogate biomarker for patient assessment and as an endpoint in chemoprevention clinical trials.
Keywords: Intraepithelial neoplasia (IEN), lung cancer, risk assessment, intermediate or pre-neoplastic markers and risk factors, biomarkers and intervention studies, chemoprevention, biomarkers and intervention, cancer surveillance and screening, chemoprevention clinical trials, quantitative image cytometry, ploidy analysis, malignancy associated changes
